This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Dr Reddy Laboratories Ltd (RDY)

NYSE: Health Care

Company Income Statement
Mar 2014 Mar 2013 Mar 2012 Mar 2011
Sales 2.21B 2.14B 1.90B 1.67B
Cost of Sales 823.18M 921.54M 751.34M 678.32M
Gross Operating Profit 1.39B 1.22B 1.15B 994.81M
Selling, General, and Administrative Expenses 648.06M 617.27M 567.49M 530.63M
Research & Development 207.24M 141.05M 116.20M 113.34M
Operating Income before D & A (EBITDA) 530.07M 457.11M 466.70M 350.83M
Depreciation & Amortization 118.74M 101.99M 102.48M 92.92M
Interest Income 27.97M 27.17M 24.12M 3.88M
Other Income - Net 0.00 0.00 15.04M 24.98M
Special Income / Charges 23.66M 32.92M -20.45M 0.00
Total Income Before Interest Expenses (EBIT) 465.87M 417.12M 383.99M 286.83M
Interest Expense 21.29M 18.71M 20.98M 8.11M
Pre-Tax Income 444.59M 398.40M 363.02M 278.72M
Income Taxes 85.12M 90.06M 82.65M 31.43M
Minority Interest 0.00 -18.38K 0.00 0.00
Net Income From Continuing Operations 359.47M 308.34M 280.37M 247.30M
Net Income From Discontinued Operations 0.00 0.00 0.00 0.00
Net Income From Total Operations 359.47M 308.34M 280.37M 247.30M
Extraordinary Income/Losses 0.00 0.00 0.00 0.00
Income From Cum. Effect of Acct. Change 0.00 0.00 0.00 0.00
Income From Tax Loss Carryforward 0.00 0.00 0.00 0.00
Other Gains / Losses 0.00 0.00 0.00 0.00
Total Net Income 359.47M 308.36M 280.37M 247.30M
Normalized Income
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
335.80M 275.42M 300.82M 247.30M
Preferred Dividends
Net Income Available To Common 359.47M 308.34M 280.37M 247.30M
Basic EPS from Continuing Ops. 2.11 1.82 1.65 1.46
Basic EPS from Discontinued Ops. 0.00 0.00 0.00 0.00
Basic EPS from Total Operations 2.11 1.82 1.65 1.46
Basic EPS from Extraordinary Inc. 0.00 0.00 0.00 0.00
Basic EPS from Cum Effect of Accounting Change 0.00 0.00 0.00 0.00
Basic EPS from Tax Loss Carryf'd. 0.00 0.00 0.00 0.00
Basic EPS from Other Gains (Losses) 0.00 0.00 0.00 0.00
Basic EPS, Total 2.11 1.82 1.65 1.46
Basic Normalized Net Income/Share 1.97 1.62 1.78 1.46
EPS fr Continuing Ops. 2.11 1.81 1.65 1.45
EPS fr Discontinued Ops 0.00 0.00 0.00 0.00
EPS fr Total Ops. 2.11 1.81 1.65 1.45
EPS fr Extraord. Inc. 0.00 0.00 0.00 0.00
EPS fr Cum Effect of Accounting Change 0.00 0.00 0.00 0.00
EPS fr Tax Loss Carfd. 0.00 0.00 0.00 0.00
EPS fr Other Gains (L) 0.00 0.00 0.00 0.00
EPS, Total 2.11 1.81 1.65 1.45
Diluted Normalized Net Inc/Shr
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
1.97 1.62 1.77 1.45
Dividends Paid per Share 0.26 0.23 0.23 0.22
RDY News

RDY Dr Reddy Laboratories Ltd

Analysts Ratings for RDY

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 0 0 1 1
Moderate Buy 0 0 0 0
Hold 1 1 1 1
Moderate Sell 1 1 1 1
Strong Sell 0 0 0 0
GET RDY ANALYST REPORT

Brokerage Partners

RDY Chatter

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs